Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FOXP1
REST API REST API
Homo sapiens
FOXP1 is differentially expressed in 233 experiments: 116 organism parts: liver, mammary gland, ... (114 more);, 118 disease states: normal, breast carcinoma, ... (116 more);, 103 cell types 379 cell lines 43 compound treatments and 63 other conditions.
Synonyms HSPC215, QRF1, hFKH1B, 12CC4
Orthologs FOXP1_BOVIN (Bos taurus)   Foxp1 (Mus musculus)   FOXP1 (Gallus gallus)   Q4H3H6_CIOIN (Ciona intestinalis)   Foxp1 (Rattus norvegicus)   FKH2 (Saccharomyces cerevisiae)   FKH1 (Saccharomyces cerevisiae)   foxp1 (Xenopus laevis)   FOXP1 (Canis familiaris)   FoxP (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term pattern specification process, embryo development, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, cardiac muscle cell differentiation, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, intracellular, transcription, DNA-dependent, metal ion binding, DNA bending activity, motor axon guidance, transcription factor binding, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, sarcomere organization, nucleus, heart development, protein heterodimerization activity, transcription factor complex, chromatin binding, protein homodimerization activity, negative regulation of transcription from RNA polymerase II promoter, skeletal muscle tissue development, positive regulation of transcription, DNA-dependent, zinc ion binding, positive regulation of mesenchymal cell proliferation, regulation of cardiac muscle cell proliferation, positive regulation of epithelial cell proliferation involved in lung morphogenesis, in utero embryonic development, immunoglobulin V(D)J recombination, ventral spinal cord development, positive regulation of immunoglobulin production, positive regulation of epithelial cell proliferation, smooth muscle tissue development, lung development, pre-B cell differentiation, sequence-specific DNA binding transcription factor activity, regulation of sequence-specific DNA binding transcription factor activity, cardiovascular system development, positive regulation of cardiac muscle cell differentiation, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term TF_fork_head
UniProt Accession Q9H334, Q8IXF4, C9J0F0, Q548T7, C9IYY1, C9J5T4, Q8N2P0, Q8NAN6, B4DMV4, A3KMG1, Q9BSG9, F5GYL1, E7ETP1, E9PFD3
Gene-Disease Assocation MENTAL RETARDATION WITH LANGUAGE IMPAIRMENT AND AUTISTIC FEATURES
Search EB-eye ENSG00000114861
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-GEOD-6919, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-19639, E-GEOD-4219, E-GEOD-3202, ... (27 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-19639
373 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-MEXP-750, ... (43 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
endothelial cell
2
E-GEOD-19240, E-GEOD-3998
CD4+ T cell
1
2
E-GEOD-16190, E-AFMX-5, E-GEOD-19069
basal cell
1
E-GEOD-3998
CD21lo transitional B cell
1
E-GEOD-17186
CD105+ endothelial
1
1
E-AFMX-5
97 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, E-MEXP-2069, ... (48 experiments)

Factor Value U/D Experiments
breast carcinoma
1
2
E-TABM-276, E-GEOD-5823, E-MTAB-37
control
1
2
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121
no atrial fibrillation
1
E-GEOD-2240
bronchogenic carcinoma
1
E-MTAB-37
Pick's disease
1
E-MEXP-2280
NDV
1
E-GEOD-18791
112 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-TABM-868, ... (22 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
control - untreated
1
E-GEOD-7216
FLAP
1
E-GEOD-3202
resveratrol
1
E-TABM-782
BCR/FGFR1
1
1
E-GEOD-15811
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
37 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
38 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-19246, E-GEOD-21374, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-TABM-868, E-TABM-601, E-GEOD-17347, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (10 experiments)

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-TABM-740, E-MEXP-2069, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-19703, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246, E-GEOD-20037

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-1315, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-12293, E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428, E-GEOD-12710

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Processing time: 0.34 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM